Compare · NVO vs PLRZ
NVO vs PLRZ
Side-by-side comparison of Novo Nordisk A/S (NVO) and Polyrizon Ltd. (PLRZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PLRZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 9485.3x PLRZ ($22.7M).
- Over the past year, NVO is down 12.1% and PLRZ is up 71.6% - PLRZ leads by 83.6 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 3 for PLRZ).
- NVO has more recent analyst coverage (25 ratings vs 0 for PLRZ).
- Company
- Novo Nordisk A/S
- Polyrizon Ltd.
- Price
- $48.65+3.65%
- $10.65+4.82%
- Market cap
- $215.46B
- $22.7M
- 1M return
- -2.08%
- -20.93%
- 1Y return
- -12.07%
- +71.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 3
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PLRZ
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
- Amendment: SEC Form SCHEDULE 13G/A filed by Polyrizon Ltd.
- SEC Form 6-K filed by Polyrizon Ltd.
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform